PEGylation of biological macromolecules

Process Chemistry in the Pharmaceutical Industry, Volume 2: Challenges in an Ever Changing Climate

Volumn , Issue , 2007, Pages 383-402

  Buckley, John J ^a   Finn, Rory F ^a   Mo, Jianming ^a   Bass, Laura A ^a   Ho, Sa V ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896105733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420008357     Document Type: Chapter

References (79)

1. Kompella, U.B. and Lee, V.H.L., Pharmacokinetics of peptide and protein drugs, in Peptide and Protein Drug Delivery, Lee, V.H.L., Ed., Marcel Dekker:New York, NY, 1991, 391-404.
2. Cleland, J.L., Daugherty, A., and Mrsny. R., Emerging protein delivery systems, Current opinion in Biotechnology, 12, 21, 2001.
3. Nucci, M. L., Shorr, R., and Aubuchowski, A. The therapeutic value of poly (ethylene glycol)-modified proteins, Adv. Drug Delivery Rev., 6, 133, 1991.
4. Inada Y, Furukawa, M., Sasaki H., Kodera, Y., Hiroto, M., Nishimura, H., Matsusshima, A., Biological and Biotechnological applications of PEG and PM-modified proteins. Tibtech. 1995;13:86-90.
5. Harris, J.M. and Chess, R.B., Effect of PEGylation on pharmaceuticals, Nat. Rev.Drug Discov., 2, 214, 2003.
6. Pasut, G., Guiotto, A., and Veronese, F. M., Protein, peptide and non-peptide drug PEGylation for therapeutic application, Expert Opinion on Therapeutic Patents, 14, 6, 859, 2004.
7. Youngster, S., Wang, Yu-Sen, Grace, M., Bausch, J., Bordens, R., Wyss, D. F. Structure, biology and therapeutic implications of PEGylated interferon Alpha-2b. Current Pharmaceutical Design 2002; 8:2139-2157.
8. Bailon, P., Palleroni, A., and Scxhaffer, C.A., Rational design of a potent, long lasting form of interferon: a 40 Kda branched polyethylene glycol conjugated interferon α-2a for the treatment of Hepatitis C, Bioconjugate Chem., 12, 195, 2001.
9. Pradghanaga, S., Wilkinson, I., and Ross, R.J.M., Pegvisomant: structure and function, Journal of Molecular Endocrinology, 29, 11, 2002.
10. Chapman, A., Antoniw, P., Spitali, M., West, S., Stephens, S., King. Therapeutic antibody fragments with prolonged half-lives, Nature Biotechnology, 1999;17:780-783.
11. Molineux G., Kinstler O., Briddell, B., Hartley, C., McElroy, P., Kerzic, P., Sutherland, w., Stoney, G., Kern, B., Fletcher, F., Cohen, A., Korach, E., Ulich, T., McNiece, I., Lockbaum, P., Miller-Messana, M. A., Gardner, S., Hunt, T., Schwab, G. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize pBPC in both mice and humans, Experimental Hematology, 27. 1999; 27:1724-1734.
12. Farese, A. M., D.B. Casey, R.M. Vigneulle, N.R. Siegel, R. F. Finn, J. A. Klover, D.Villani-Price, W.G. Smith, J. P. McKearn and T. J. MacVittie. 2001. A Single Dose of PEGylated Leridistim Significantly Improves Neutrophil Recovery in Sublethally Irradiated Rhesus Macaques, Stem Cells, 19: 514-521.
13. Yang, Z., Wang, J., Lu, J., Kobayashi, y., Takakura, T., Takimoto, A., Yoshioka, T., Lian, C., Chen, C., Zhang, d., Zhang, Y., Li, s., sun, x., Tan, Y., Yagi, S., Frenkel, E., Hoffman, R. M. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methionase in primates, Cancer Research, 2004; 64:6673-6678.
14. Aubuchowski, A., van Es, T., Palczuk, N.C., and Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol, J. Biol. Chem., 1977; 252:3578-3581.
15. Katre N.V., Knauf, M.J., and Laird, W.J., Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine meth A sarcoma model, Proc. Natl. Acad. Sci. USA, 84, 1487, 1987.
16. Caliceti, P., Veronese, F.M., and Jonak, Z., Immunogenic and tolerogenic properties of monomethoxypoly (ethylene glycol) conjugated proteins, Il Farmaco, 54, 430, 1999.
17. Knauf, M.J., Bell, D.P., Hirtzer, P., Luo, ZP., Young, J.D., Katres N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers, J. Biol Chem., 1988;263; 29:15064-15070.
18. Clark, R., Olson, K., Fuh, G., Marian, M., Mortensen, D., Teshima, G., Chang, S., Chu, H., Mukku, V., Canova-Davis, E., Somers T., Cronin, M., Winkler, M., Wells J. A. Long-acting growth hormones produced by conjugation with polyethylene glycol, J. Biol. Chem., 1996; 271:21969-21977.
19. Katre N.V., Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol, Journal of Immunology, 144, 209, 1990.
20. Hinds K.D. and Kim, S.W., Effects of PEG conjugation on insulin properties, Advanced Drug Delivery review, 54, 505, 2002.
21. Guerra, P.I., Acklin, C., Kosky, A.A., Davis, J. M., Treuheit, M.J., Brems, D.N. PEGylation prevents N-terminal degradation of megakaryocyte growth and development factor, Pharmaceutical Research, 1998;15;12: 1822-1827.
22. Heller, M.C., Carpenter, J.F., and Randolph, T.W., Conformational stability of lyophilized PEGylated proteins in a phase-separating system, Journal of Pharmaceutical Sciences, 88, 58, 1999.
23. Brown, Larry R., Commercial challenges of protein drug delivery, Expert Opinion on Drug Delivery, 2, 29, 2005.
24. Zalipsky, S., Seltzer, R. and Menon-Rudolph, S., Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins, Biotechnology and Applied Biochemistry, 15(1), 100, 1992.
25. Morpurgo, M. and Veronese, F.M., Conjugates of peptides and proteins to polyethylene glycols, in Methods in Molecular Biology, Totowa, NJ, United States, Bioconjugation Protocols, 283, 45, 2004, Humana Press Inc.
26. Veronese, F.M., Peptide and protein PEGylation. A review of problems and solutions, Biomaterials, 22, 405, 2001.
27. Veronese, F.M. and Harris, J.M., Introduction and overview of peptide and protein PEGylation, Advanced Drug Delivery Reviews, 54, 453, 2002.
28. Roberts, M.J., Bentley, MD., and Harris, J.M., Chemistry for peptide and protein PEGylation, Advanced Drug Delivery Reviews, 54, 459, 2002.
29. Francis G E; Fisher D; Delgado C; Malik F; Gardiner A; Neale D. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques. International journal of hematology (1998), 68(1), 1-18.
30. Sperinde, J.J., Martens, B.D. and Griffith, L.G., Tresyl-mediated synthesis: Kinetics of competing coupling and hydrolysis reactions as a function of pH, temperature, and steric factors, Bioconjugate Chemistry, 10, 213, 1999.
31. Wang, Yu-Sen; Youngster, Stephen; Bausch, James; Zhang, Rumin; McNemar, Charles; Wyss, Daniel F. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry (2000), 39(35), 10634-10640.
32. Saifer, Mark G. P.; Williams, L. David; Sherman, Merry R.; French, John A.; Kwak, Larry W.; Oppenheim, Joost J. Improved conjugation of cytokines using high molecular weight poly(ethylene glycol): PEG-GM-CSF as a prototype. Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (1997), 38(1), 576-577.
33. Delgado, C., Francis, G.E. and Fisher, D., The uses and properties of PEG-linked proteins, Critical Reviews in Therapeutic Drug Carrier Systems, 9, 249, 1992.
34. Dolence, Eric K.; Hu, Chen-Ze; Tsang, Ray; Sanders, Clifton G.; Osaki, Shigemasa. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and polymer surfaces. (Surface Engineering Technologies, Division of Innerdyne, Inc., USA). US patent 55650234 1997.
35. Shuai, Xintao; Merdan, Thomas; Unger, Florian; Wittmar, Matthias; Kissel, Thomas. Novel Biodegradable Ternary Copolymers hy-PEI-g-PCL-b-PEG: Synthesis, Characterization, and Potential as Efficient Nonviral Gene Delivery Vectors, Macromolecules, (2003), 36(15), 5751-5759.
36. Abuchowsk, i A.; McCoy, J.R.; Palczuk, N.C.; van Es, T.; Davis, F.F., Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, Journal of Biological Chemistry, (1977), 252(11), 3582-6.
37. Veronese, F.M.; Largajolli, R.; Boccu, E.; Benassi, C.A.; Schiavon, O., Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase, Applied Biochemistry and Biotechnology, (1985), 11(2), 141-52.
38. Beauchamp, C.O.; Gonias, S.L.; Menapace, D.P.; Pizzo, S.V., A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Analytical biochemistry (1983), 131(1), 25-33. Journal code: 0370535. ISSN:0003-2697.
39. Zalipsky, S. and Barany, G., Facile synthesis of α-hydroxy ω-carboxymethyl poly(ethylene oxide), Journal of Bioactive and Compatible Polymers, 5(2), 227, 1990.
40. Vincent, G. and Philippe, T., Pegvisomant Pfizer/Sensus, Current Opinion in Investigational Drugs, (London, England:2000), 5(4), 463, 2004.
41. Dhalluin, Christophe; Ross, Alfred; Leuthold, Luc-Alexis; Foser, Stefan; Gsell, Bernard; Mueller, Francis; Senn, Hans. Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers, Bioconjugate Chemistry (2005), 16(3), 504-517.
42. Lee, Haeshin; Jang, Il Ho; Ryu, Sung Ho; Park, Tae Gwan. N-terminal site-specific mono-PEGylation of epidermal growth factor, Pharmaceutical Research (2003), 20(5), 818-825.
43. Kinstler Olaf; Molineux Graham; Treuheit Michael; Ladd David; Gegg Colin, Mono-N-terminal poly(ethylene glycol)-protein conjugates, Advanced Drug Delivery Reviews (2002), 54(4), 477-85.
44. Arutselvan, N.; Xiong Cheng-Yi; Albrecht Huguette; DeNardo Gerald L; DeNardo Sally J Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals, Bioconjugate Chemistry (2005), 16(1), 113-21.
45. Morpurgo, Margherita; Veronese, Francesco M.; Kachensky, David; Harris, J. Milton. Preparation and Characterization of Poly(ethylene glycol) Vinyl Sulfone, Bioconjugate Chemistry (1996), 7(3), 363-368.
46. Kogan, T.P., Synthesis of substituted methoxypolyethylene glycol derivatives suitable for selective protein modification, Synthetic Communications, 22(16), 2417, 1992.
47. Rosendahl, Mary S.; Doherty, Daniel H.; Smith, Darin J.; Bendele, Alison M.; Cox, George N. Sitespecific protein PEGylation: Application to cysteine analogs of recombinant human granulocyte colony-stimulating factor, BioProcess International (2005), 3(4), 52-56, 58-60, 62.
48. Hinds, K.D., Protein conjugation, cross-linking, and PEGylation, in Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids, Mahato, R.I., Ed. CRC Press LLC, Boca Raton, Fla, 2005, 119-185.
49. Zalipsky, S. and Barany, G., Preparation of polyethylene glycol derivatives with two different functional groups at the termini, Polymer Preprints (American Chemical Society, Division of Polymer Chemistry), 1986, 27(1), 1-2.
50. Felix, A.M. and Bandaranayake, R.M., Synthesis of symmetrically and asymmetrically branched PEGylating reagents, Theoretical and Applied Science, Journal of Peptide Research, 63(2), 85, 2004
51. Kaul, G. and Amiji, M., Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery, Pharmaceutical Research, 19(7), 1061, 2002.
52. Pardridge, W.M., Wu, D. and Sakane, T., Combined use of carboxyl-directed protein PEGylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, Pharmaceutical Research, 15(4), 576, 1998.
53. Liu, Y., Franzen, S. and Feldheim, D.L., Preparation and characterization of mixed monolayers of PEG and peptides on gold nanoparticles, in Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005, 2005.
54. Bhadra, D., Bhadra, S. and Jain, N.K., PEGylated peptide-based dendritic nanoparticulate systems for delivery of artemether, Journal of Drug Delivery Science and Technology, 15(1), 65-2005.
55. Greenwald, R.B., Pendri, A. and Bolikal, D., Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates, Journal of Organic Chemistry, 60(2), 331, 1995.
56. Youngster, S., Wang, Yu-Sen, Grace, M., Bausch, J., Bordens, R., Wyss, D. F., Structure, biology and therapeutic implications of PEGylated interferon alpha-2b, Current Pharmaceutical Design, 8, 2139, 2002.
57. Fee, C.J. and Van Alstine, J.M., PEG-proteins: Reaction Engineering and separation issues, Chemical Engineering Science, 61, 924, 2006.
58. Ken Hinds, Ken; Koh, Jae Joon; Joss, Lisa; Liu, Feng; Baudys, Miroslav and Kim, Sung Wan. Synthesis and Characterization of Poly(ethylene glycol)-Insulin Conjugates, Bioconjugate Chem., 11, 195-201 (2000)
59. Gioacchini, Anna Maria; Carrea, Giacomo; Secundo, Francesco; Baraldini, Mario and Roda1, Aldo. Electrospray Mass Spectrometric Analysis of Poly(ethylene Glycol)-Protein Conjugates. Rapid Communication in Mass Spectrometry, 11, 1219-1222 (1997)
60. Lee H. and Parg, T. G., Preparation and characterization of mono-pegylated epidermal growth factor:evaluation of in vitro biologic activity, Pharmaceutical Research, 19, 845, 2002.
61. Wang, Yu-Sen; Youngster, Stephen; Grace, Michael, et. al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications, Advanced Drug Delivery Reviews, 54 (2002) 547-570.
62. Bass, L., Strategy for Evaluation of Analytical Comparability of PEGylated Biomolecules, presented at International Association for Biologicals: State of the Art Analytical Methods for the Characterization of Biological Products and Assessment of Comparability, NIH, Bethesda, Maryland, June 2006.
63. Manjula, B,. Tsai, A., Upadhya, K., Perumalsamy, P. K., Malavalli, A., Vandegriff, K., Winslow, R. M., Intaglietta, M.J., Prabhakaran, M., Friedman, J.M., Acharya, A.S. Site-specific PEGylation of Hemoglobin at Cys -93 (Β): Correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain, Bioconjugate Chem., 14 464-472, 2003.
64. Kinstler O., Molineux G., Treuheit M., Ladd D., Gegg C. Mono-N-terminal poly(ethylene glycol)- protein conjugates, Advanced drug delivery reviews (2002), 54(4), 477-85.
65. Han, S., Thermal/oxidative degradation and stabilization of polyethylene glycol, Polymer, 38(2), 317, 1997.
66. Goodson, R.J. and Katre, N.V., Site directed PEGylation of recombinant interleukin-2 at its glycosylation site, Biotechnology, 8(4), 343, 1990.
67. Tsutsumi, Y., Onda, M., Nagata, S., Lee, B., Kreitman R.J., Pastan, I. Site -specific chemical modification with polyethylene glycol of recombinant immunotoxins anti-Tac(Fv) -PE38 (LMB-2)_improves antitumor and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci., 2000; 18,97,15: 8548-8553.
68. Natarajan, A., Xiong, C-Y, Albrecht, H. DeNardo, G. L., DeNardo, S. J., Characterization of Site-Specific ScFc PEGylation for Tumor targeting Pharmaceuticals, Bioconjugate Chem., 2005; 16:113-121.
69. Cazalis, C. S., Haller, C. A., Sease-Cargo, L., Chaik of, E.L. C terminal Site Specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity, Bioconjugate Chem., 2004; 15:1005-1009.
70. Sato, H., Enzymatic procedure for site specific PEGylation of proteins, Adv. Drug Deliv. Rev., 54, 487, 2002.
71. Wang, L., Zhang, Z., Ansger, B., Schultz, P.G. Addition of the keto functional group to the genetic code of Escherichia coli, PNAS, 2003, 100; 1:56-61.
72. Kodera, Y., Sekine, T., Yasokochi, T., Kiriu, Yoshihiro, Hiroto, Misao, Matsushima, A., Inada, Y., Stabilization of L-Aspariginase modified with comb shaped poly(ethylene glycol) derivatives, in Vivo and in Vitro, Bioconjugate Chem., 1994;5:283-286.
73. Lee, E.K. and Lee, J.D., Solid-phase, N-terminus-specific, mono-PEGylation of recombinant interferon- alpha-2a: Purification, characterization, and bioactivity, presented at Int. Symp. on the Separation of Proteins, Peptides and Polynucleotides, Aachen, Federal Republic of Germany, Oct 19-22, 2004.
74. Fee, C.J., Size-exclusion reaction chromatography (SERC): A new technique for protein PEGylation, Biotechnology & Bioengineering, 82(2), 200, 2003.
75. Baran, E.T., Ozer, N. and Hasirci, V., Solid-phase enzyme modification via affinity chromatography, Journal of Chromatography B, 794(2), 311, 2003.
76. Felix, A.M., Site-specific poly(ethylene glycol)ylation of peptides, in Poly(ethylene glycol) ACS Symposium series 680, Harris, J.M. and Zalipsky, S., Eds., American Chemical Society, Washington, D.C., 1997, 218-238.
77. Monkarsh, S.P., Spence, C., Porter, J.E., Palleroni, A., Nalin, C., Rosen, P. and Bailon, P. (1997). Isolation of positional isomers of mono-poly(ethylene glycol)ylated interferon/α-2a and the determination of their biochemical and biological characteristics, in: Harris, J.M. and Zalipsky, S., (Eds.), Poly(ethylene glycol) ACS Symposium series 680, American Chemical Society, Washington, D.C. 207-216.
78. Delgado, C., Malmsten, M. and Van Alstine, J.M., Analytical partitioning of poly(ethylene glycol)- modified proteins, Journal of Chromatography B, 692(2), 263, 1997.
79. Gepasi 3.30, (Bio)chemical Kinetics Simulation Software written by Pedro Mendes, University of Wales Aberystwyth., downloadable at http:/www.gepasi.org.